Affinity maturation of an ERBB2-targeted SPECT imaging peptide by in vivo phage display

Molecular Imaging and Biology

Volumn 16, Issue 4, 2014, Pages 449-458

  Larimer, Benjamin M ^a,b   Thomas, William D ^c   Smith, George P ^c   Deutscher, Susan L ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b University of Missouri   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

Author keywords

Affinity maturation; Breast cancer; In vivo phage display; Molecular imaging; Peptide; SPECT

Indexed keywords

AMINO ACID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; RADIOPHARMACEUTICAL AGENT; TETRAXETAN 1 DO3 IN 111; TETRAXETAN 3 GO3 IN 111; TETRAXETAN KCCYSL IN 111; UNCLASSIFIED DRUG; COORDINATION COMPOUND; IMMOBILIZED PROTEIN; INDIUM-111-1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAACETIC ACID; PEPTIDE; PROTEIN BINDING; SINGLE HETEROCYCLIC RINGS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIOPHAGE; BINDING AFFINITY; BINDING ASSAY; BONE; BREAST CARCINOMA; CANCER CELL; CELL MATURATION; COMPARATIVE STUDY; DRUG DISTRIBUTION; DRUG UPTAKE; HEART; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY TUBULE ABSORPTION; LUNG; MOLECULAR IMAGING; MOUSE; MUSCLE; NONHUMAN; PHAGE DISPLAY; PLASMA CLEARANCE; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIOISOTOPE DISTRIBUTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPECT SCANNER; TISSUE SPECIFICITY; TUMOR XENOGRAFT; AMINO ACID SEQUENCE; ANIMAL; BIOTINYLATION; BREAST TUMOR; CELL SURFACE DISPLAY; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; RADIOGRAPHY; SCID MOUSE; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL LINE;

MUS;

AMINO ACID SEQUENCE; ANIMALS; BIOTINYLATION; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURFACE DISPLAY TECHNIQUES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COORDINATION COMPLEXES; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; IMMOBILIZED PROTEINS; KIDNEY; MICE, SCID; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN BINDING; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84904426505     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-014-0724-5     Document Type: Article

References (42)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10-29
2. Alroy I (1997) The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 410:83
3. Graus-Porta D, Beerli RR, Daly JM, Hynes NE (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16:1647-1655 (Pubitemid 27151960)
4. Hynes NE, Stern DF (1994) The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198:165-184
5. Witton CJ, Reeves JR, Going JJ et al (2003) Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 200:290-297 (Pubitemid 36827302)
6. Milenic DE, Yokota T, Filpula DR et al (1991) Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 51:6363-6371
7. Fujimori K (1990) A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 31:1191
8. Landon LA, Zou J, Deutscher SL (2004) Is phage display technology on target for developing peptide-based cancer drugs? Curr Drug Dis Technol 1:113-132
9. Landon LA, Deutscher SL (2003) Combinatorial discovery of tumor targeting peptides using phage display. J Cell Biochem 90:509-517 (Pubitemid 37243698)
10. Peletskaya E, Glinsky G, Deutscher S, Quinn T (1996) Identification of peptide sequences that bind the Thomsen-Friedenreich cancer-associated glycoantigen from bacteriophage peptide display libraries. Mol Divers 2:13-18 (Pubitemid 126817060)
11. Ruoslahti E (2000) Targeting tumor vasculature with homing peptides from phage display. Semin Cancer Biol 10:435-442
12. Karasseva NG, Glinsky VV, Chen NX et al (2002) Identification and characterization of peptides that bind human ErbB-2 selected from a bacteriophage display library. J Protein Chem 21:287-296 (Pubitemid 34839925)
13. Kumar SR, Quinn TP, Deutscher SL (2007) Evaluation of an 111In-radiolabeled peptide as a targeting and imaging agent for ErbB-2 receptor-expressing breast carcinomas. Clin Cancer Res 13:6070-6079 (Pubitemid 350075064)
14. Deutscher SL, Figueroa SD, Kumar SR (2009) 111In-labeled KCCYSL peptide as an imaging probe for ErbB-2-expressing ovarian carcinomas. J Label Compd Radiopharm 52:583-590
15. Kocks C, Rajewsky K (1988) Stepwise intraclonal maturation of antibody affinity through somatic hypermutation. Proc Natl Acad Sci U S A 85:8206-8210
16. Landon LA, Peletskaya EN, Glinsky VV et al (2003) Combinatorial evolution of high-af fi nity peptides that bind to the Thomsen-Friedenreich carcinoma antigen. J Protein Chem 22:193-204 (Pubitemid 38115216)
17. Smith GP G.P. Smith Phage Display Website. http://www.biosci.missouri. edu/smithGP/PhageDisplayWebsite/PhageDisplayWebsiteIndex.html
18. Newton JR, Kelly KA, Mahmood U et al (2006) In vivo selection of phage for the optical imaging of PC-3 human prostate carcinoma in mice. Neoplasia 8:772-780 (Pubitemid 44465528)
19. Altschul SF, Gish W, Miller W et al (1990) Basic local alignment search tool. J Mol Biol 215:403-410
20. Huang J, Ru B, Li S, Lin H, Guo F-B (2010) SAROTUP: scanner and reporter of target-unrelated peptides. J Biomed Biotechnol. doi:10.1155/2010/101932
21. Franklin MC, Carey KD, Vajdos FF et al (2004) Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5:317-328 (Pubitemid 38482068)
22. Cho H-S, Mason K, Ramyar KX et al (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421:756-760 (Pubitemid 36227628)
23. Molina MA, Codony-Servat J, Albanell J et al (2001) Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res 61:4744-4749 (Pubitemid 32691885)
24. Lobo ED, Hansen RJ, Balthasar JP (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93:2645-2668 (Pubitemid 39506617)
25. Zhang X, Cabral P, Bates M et al (2010) In vitro and in vivo evaluation of [99mTc (CO) 3]-radiolabeled ErbB-2-targeting peptides for breast carcinoma imaging. Curr Radiopharm 3:308-321
26. Vegt E, de Jong M, Wetzels JFM et al (2010) Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med 51:1049-1058
27. Miao Y, Fisher DR, Quinn TP (2006) Reducing renal uptake of 90Y-and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues. Nucl Med Biol 33:723-733 (Pubitemid 44247740)
28. Hoffman TJ, Gali H, Smith CJ et al (2003) Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J Nucl Med 44:823-831 (Pubitemid 39655218)
29. Froidevaux S, Eberle AN, Christe M et al (2002) Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model. Int J Cancer 98:930-937 (Pubitemid 34286693)
30. Good S, Walter MA, Waser B et al (2008) Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours. Eur J Nucl Med 35:1868-1877
31. Chen J, Cheng Z, Owen NK et al (2001) Evaluation of an 111In- DOTA-rhenium cyclized α-MSH analog: a novel cyclic-peptide analog with improved tumor-targeting properties. J Nucl Med 42:1847-1855 (Pubitemid 34016356)
32. Deutscher SL (2010) Phage display in molecular imaging and diagnosis of cancer. Chem Rev 110:3196-3211
33. Derda R, Tang S, Li SC, Ng S et al (2011) Diversity of phage-displayed libraries of peptides during panning and amplification. Molecules 16:1776-1803
34. Olsen JO, Pozderac RV, Hinkle G et al (1995) Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Semin Nucl Med 25:251-261
35. Liu S, Edwards DS (1999) 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev 99:2235-2268
36. Yu D, Hung M-C (2000) Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 19:6115
37. Krenning EP, Kwekkeboom DJ, Bakker WH et al (1993) Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716-731 (Pubitemid 23284773)
38. Béhé M, Becker W, Gotthardt M et al (2003) Improved kinetic stability of DTPA-dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives. Eur J Nucl Med Mol Imaging 30:1140-1146 (Pubitemid 36988226)
39. Ferro-Flores G, de Murphy CA, Rodr̀guez-Cortès J et al (2006) Preparation and evaluation of 99mTc-EDDA/HYNIC-[Lys3]-bombesin for imaging gastrin-releasing peptide receptor-positive tumours. Nucl Med Commun 27:371-376 (Pubitemid 44315047)
40. Thakur ML, Aruva MR, Gariepy J et al (2004) PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog. J Nucl Med 45:1381-1389 (Pubitemid 47618539)
41. Rolleman E, Valkema R, de Jong M et al (2003) Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 30:9-15 (Pubitemid 36692887)
42. Vegt E, van Eerd JEM, Eek A et al (2008) Reducing renal uptake of radiolabeled peptides using albumin fragments. J Nucl Med 49:1506-1511